YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage

Current standard of care for muscle-invasive urothelial cell carcinoma (UCC) is surgery along with perioperative platinum-based chemotherapy. UCC is sensitive to cisplatin-based regimens, but acquired resistance eventually occurs, and a subset of tumors is intrinsically resistant. Thus, there is an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciamporcero, Eric, Shen, He, Ramakrishnan, Swathi, Ku, Sheng Yu, Chintala, Sreenivasulu, Shen, Li, Adelaiye, Remi, Miles, Kiersten Marie, Ullio, Chiara, Pizzimenti, Stefania, Daga, Martina, Azabdaftari, Gissou, Attwood, Kris, Johnson, Candace, Zhang, Jianmin, Barrera, Giuseppina, Pili, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695331/
https://www.ncbi.nlm.nih.gov/pubmed/26119935
http://dx.doi.org/10.1038/onc.2015.219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695331/
https://www.ncbi.nlm.nih.gov/pubmed/26119935
http://dx.doi.org/10.1038/onc.2015.219

Ejemplares similares